Results 11 to 20 of about 4,676,099 (307)

Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis. [PDF]

Transplant Direct, 2018
Background Variation in the use of immunosuppression regimens after liver transplant has not been well described. Methods Immunosuppression regimens used after liver transplant were identified in a novel database integrating national transplant registry ...
Nazzal M, Lentine KL, Naik AS, Ouseph R, Schnitzler MA, Zhang Z, Randall H, Dharnidharka VR, Segev DL, Kasiske BL, Hess GP, Alhamad T, McAdams-Demarco M, Axelrod DA.   +13 more
europepmc   +4 more sources

Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis. [PDF]

J Nephrol, 2022
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The Kidney Disease Improving Global Outcomes guidelines recommend rituximab or cyclophosphamide and steroids, or calcineurin inhibitor-based therapy. However, there have
Bose B, Chung EYM, Hong R, Strippoli GFM, Johnson DW, Yang WL, Badve SV, Palmer SC.   +7 more
europepmc   +2 more sources

Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review [PDF]

Frontiers in Oncology, 2021
Background and Aims: This study aimed at comparing the efficacy and safety of eltrombopag (EPAG) plus immunosuppressive therapies (ISTs) and haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the frontline treatment for severe ...
Yuan Yang, Ji Jiang, Zengwei Tang, Bing Han   +3 more
doaj   +4 more sources

Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy [PDF]

Journal of Transplantation, 2013
Background. No studies have evaluated the impact of multiple generic immunosuppression medications on transplant coordinators (TCs) and patients. Methods.
K. Parker, E. A. Zagadailov, A. S. Bruno, A. M. Wiland   +3 more
doaj   +3 more sources

Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Long‐term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long‐term corticosteroid‐sparing immunosuppression in CS is unknown.
David G. Rosenthal, Purvi Parwani, Tyler O. Murray, Bradley J. Petek, Bryan S. Benn, Teresa De Marco, Edward P. Gerstenfeld, Munir Janmohamed, Liviu Klein, Byron K. Lee, Joshua D. Moss, Melvin M. Scheinman, Henry H. Hsia, Van Selby, Laura L. Koth, Miguel H. Pampaloni, Julie Zikherman, Vasanth Vedantham   +17 more
doaj   +3 more sources

CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment

Journal of Extracellular Vesicles, 2022
Research on tumour cell‐derived small extracellular vesicles (sEVs) that regulate tumour microenvironment (TME) has provided strategies for targeted therapy of head and neck squamous cell carcinoma (HNSCC).
Tingwei Lu, Zhen Zhang, Jianjun Zhang, Xinhua Pan, Xueqin Zhu, Xu Wang, Zhihui Li, Min Ruan, Huasheng Li, Wantao Chen, Ming Yan   +10 more
doaj   +2 more sources

Gut microbiota modulation in cardiac cell therapy with immunosuppression in a nonhuman primate ischemia/reperfusion model [PDF]

npj Regenerative Medicine
Gut microbiota affect transplantation outcomes; however, the influence of immunosuppression and cell therapy on the gut microbiota in cardiovascular care remains unexplored.
Hung-Chih Chen, Yu-Che Cheng, Marvin L. Hsieh, Po-Ju Lin, Emily F. Wissel, Theodore Steward, Cindy M. C. Chang, Jennifer Coonen, Timothy A. Hacker, Timothy J. Kamp, Patrick C. H. Hsieh   +10 more
doaj   +2 more sources

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2017
Significance Therapies that activate the host immune system have shown tremendous promise for a variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these immunotherapies.
Meredith L. Stone, Katherine B. Chiappinelli, Huili Li, Lauren Murphy, Meghan Travers, Michael J. Topper, Dimitrios Mathios, Michael Lim, Ie‐Ming Shih, Tian‐Li Wang, Chien‐Fu Hung, Vipul Bhargava, Karla R. Wiehagen, Glenn S. Cowley, Kurtis E. Bachman, Reiner Strick, Pamela L. Strissel, Stephen B. Baylin, Cynthia A. Zahnow   +18 more
openalex   +2 more sources

Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy [PDF]

Nephrology, Dialysis and Transplantation, 2011
BACKGROUND Regulatory T cells have been suggested to down-regulate the alloimmune response. The aim of this prospective open study was to evaluate the effects of different inductive agents on peripheral blood regulatory T cells in kidney transplant ...
E. Krystufkova, Alena Sekerková, Ilja Střı́ž, I. Brabcova, Eva Girmanová, Ondřej Viklický   +5 more
openalex   +2 more sources

Successful recovery from severe COVID‐19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab

Transplant Infectious Disease, 2020
Although immunosuppressed patients may be more prone to SARS‐CoV‐2 infection with atypical presentation, long‐term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID‐19.
Andrea Lauterio, M. Valsecchi, S Santambrogio, Riccardo De Carlis, Marco Merli, Angelo Calini, Leonardo Centonze, Vincenzo Buscemi, Maurizio Bottiroli, Massimo Puoti, Roberto Fumagalli, Luciano De Carlis   +11 more
openalex   +2 more sources